56872-27-6

Usage

Chemical Properties

White Solid

InChI:InChI=1/C13H10BrClO/c14-11-6-7-13(12(15)8-11)16-9-10-4-2-1-3-5-10/h1-8H,9H2

Upstream product

• 3964-56-5 4-bromo-2-chlorophenol 
• 100-39-0 benzyl bromide 
• 95-57-8 2-monochlorophenol 
• 100-44-7 benzyl chloride 

Downstream Products

• 220214-82-4 3-[(4-benzyloxy-3-chloro-phenyl)-hydroxy-methyl]-1-oxa-4-aza-spiro[4.5]decane-4-carboxylic acid tert-butyl ester 
• 197778-01-1 3-[(4-benzyloxy-3-chloro-phenyl)-hydroxy-methyl]-1-oxa-4-aza-spiro[4.5]decane-4-carboxylic acid tert-butyl ester 
• 800371-67-9 1-(4-benzyloxy-3-chlorophenyl)piperazine 
• 197777-87-0 (2R,3R)-3-(4-benzyloxy-3-chlorophenyl)-2-tert-butoxycarbonylamino-3-hydroxypropionic acid 
• 197778-02-2 (2S,3R)-3-acetoxy-3-(4-benzyloxy-3-chlorophenyl)-2-tert-butoxycarbonylaminopropan-1-ol 
• 197778-03-3 (2R,3R)-3-Acetoxy-3-(4-benzyloxy-3-chloro-phenyl)-2-tert-butoxycarbonylamino-propionic acid 
• 197777-86-9 (2S,3R)-3-acetoxy-3-(4-benzyloxy-3-chlorophenyl)-2-tert-butoxycarbonylamino-1,2-cyclohexylidenepropan-1-ol 
• 197777-97-2 (2S,3S)-3-acetoxy-3-(4-benzyloxy-3-chlorophenyl)-2-tert-butoxycarbonylamino-1,2-cyclohexylidenepropan-1-ol 
• 220214-87-9 (2R,3R)-3-acetoxy-3-(4-benzyloxy-3-chlorophenyl)-2-tert-butoxycarbonylaminopropan-1-ol 
• 220214-85-7 3-(4-benzyloxy-3-chloro-benzoyl)-1-oxa-4-aza-spiro[4.5]decane-4-carboxylic acid tert-butyl ester 
• 220214-81-3 (2S)-3-(4-benzyloxy-3-chlorophenyl)-2-tert-butoxycarbonylamino-1,2-cyclohexylidene-3-oxopropan-1-ol 
• 220214-86-8 (R)-3-[(R)-(4-Benzyloxy-3-chloro-phenyl)-hydroxy-methyl]-1-oxa-4-aza-spiro[4.5]decane-4-carboxylic acid tert-butyl ester 
• 220214-80-2 (S)-3-[(S)-(4-Benzyloxy-3-chloro-phenyl)-hydroxy-methyl]-1-oxa-4-aza-spiro[4.5]decane-4-carboxylic acid tert-butyl ester 
• 220214-84-6 (2R,3R)-3-acetoxy-3-(4-benzyloxy-3-chlorophenyl)-2-tert-butoxycarbonylamino-1,2-cyclohexylidenepropan-1-ol 

Relevant academic research and scientific papers

Phosphoramidate prodrug of nucleoside analogues, a pharmaceutical composition and applications of the phosphoramidate prodrug

The invention relates to phosphoramidate prodrug of nucleoside analogues, or stereoisomers of the phosphoramidate prodrug, or a mixture of the stereoisomers of the phosphoramidate prodrug, or pharmaceutically acceptable salts or solvates of the phosphoramidate prodrug, and applications in the preparation of medicine for preventing or treating hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV) infection alone or in combination with other medicine. The anti-HBV activity of the compound of the invention is equivalent to that of tenofovir alafenamide fumarate (TAF), and the compoundof the invention has the anti-liver fibrosis effect, can help improve the therapeutic effect of patients, and has good safety important clinical significance.

Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode

On the basis of Ibrutinib’s core pharmacophore, which was moderately active to EGFR T790M mutant, we discovered novel epidermal growth factor receptor (EGFR) inhibitor compound 19 (CHMFL-EGFR-202), which potently inhibited EGFR primary mutants (L858R, del

NOVEL OLEFIN DERIVATIVE

The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R1 is substituted or unsubstituted aryl etc., R2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R4 and R5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R13 is hydrogen, substituted or unsubstituted alkyl etc., X5 is bond etc., R7 is hydrogen or substituted or unsubstituted alkyl, R8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

Discovery of 5-HT6 receptor ligands based on virtual HTS

Based on a pharmacophore alignment on a 5-HT6 ligand applying 4SCan technology, a new lead series was identified and further structurally investigated. Kis down to 8 nM were achieved.

PESTICIDAL SUBSTITUTED PHENYLETHERS

The invention relates to the use of phenylether derivatives of formula (I), to compositions thereof for the control of pests, including arthropods and helminths.

KINASE MODULATORS AND METHODS OF USE

The present invention relates to compounds of the Formula I and II wherein R, R21, R25-R33, m, n, X21-X23, and Q1 are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.

A new stereoselective synthetic strategy for β-hydroxy-α-amino acids of vancomycin

The synthesis of syn and anti β-hydroxy-α-amino acids representing rings C and E of vancomycin has been achieved starting from (R)- and (S)Garner's aldehydes by a stereocontrolled Grignard arylation reaction.

6-(3-SUBSTITUTED AMINO-2-HYDROXYPROPOXYARYL)-4,5-DIHYDRO-3(2H)-PYRIDAZINONES

The compounds are 6-(3-substituted amino-2-hydroxypropoxyaryl)-4,5-dihydro-3(2H)-pyridazinones which are β-adrenergic blocking agents.